Other
Deafness
7
Pipeline Programs↗
3
Active Trials↗
2
Companies Involved↗
Deafness is an early-stage landscape with 7 programs across 2 companies. The most active players are Pfizer, Eisai. 2 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 11
Phase 2
No programs
Phase 33
Analysis
Trial Status
7
clinical trials
Completed2 · 29%
Not yet recruiting2 · 29%
Terminated1 · 14%
Unknown status1 · 14%
Recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1·NCT06707389·30 enrolled
Effect of Ultrasound-guided Stellate Ganglion Block Combined With Facial Nerve and Glossopharyngeal Nerve Block on the Treatment of Sudden Deafness
Unknown status·—·N/A·NCT05623384·90 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)